Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Evaluation of CML Patients in the National Compassionate Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CML Ph+ patients in chronic phase~* 18 years old or older~* Patients have received either Dasatinib or Nilotinib and resulted resistant or not tolerant to the drugs or have developed the T3151 mutation~* Patients have started Ponatinib at least 12 months before registration~* Informed consent signed at registration~Exclusion Criteria:~* CML Ph+ patients in accelerated or blast phase with acute lymphoblastic leukemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CML ph+ patients (Type: None): Chronic myeloid leukemia patients who are philadelphia positive

Based on this trial design, predict the completion outcome and termination type (if applicable).